MedX Health Corp. and Medical Marketing Berlin Sign Letter of Intent (LOI)
for the North American Marketing Rights to Cardiology Telemedicine Technology

H'andy sana 211 cell phone with integrated ECG capability

MISSISSAUGA, ON, July 29 /CNW/ - MedX Health Corp., (TSXV.MDX) a global leader in drug free, non-invasive low level laser and light therapy for tissue repair and pain relief, announced today that they have signed a Letter of Intent (LOI) with Medical Marketing Berlin GmbH (MMB) for the exclusive North American marketing rights to the H'andy sana 211, a touch screen cell phone with an integrated ECG, a drug reminder and a "Health Suite" in which blood glucose, cholesterol and blood pressure, etc, can be managed.

Medical Marketing Berlin had previously obtained the worldwide rights for this technology. The device allows cardiac patients to measure an ECG in a critical situation remotely, and to send it via SMS to a telemedicine centre, hospital, or private physician to receive an immediate evaluation.

"We are pleased to have a signed Letter of Intent with MMB to bring this important product to North America. Cardiology experts agree that the remote monitoring capabilities by devices, such as the H'andy sana 211 will reduce the cost of care for the health care system, by allowing patients to reduce the number of unnecessary office visits and expensive tests, as well as by identifying problems earlier before a crisis exits, This agreement gives us a strategic entry into this important market," stated Steve Guillen, president and CEO of MedX Health Corp.

A final agreement will be subject to TSX Exchange, Board, and shareholder approvals as well as any required third-party consents, satisfactory due diligence, and the signing of a definitive agreement.

About H'andy sana 211

A comparison study demonstrated that the 1-lead ECG via the H'andy sana produced identical results with the corresponding leads of a standard 12-lead ECG record. Both ECG records were tested in parallel under clinical conditions. Following the study, Dr. Hans Lehmkuhl, chief cardiologist at the German Heart Centre in Berlin, Germany stated that he was "impressed and satisfied with the quality of the ECG recordings using the H'andy sana phone."

The H'andy sana 211 has a 2.8 inch full touch screen and full-fledged mobile phone capabilities, including a multimedia suite, internet browser, calendar, built-in camera with screen viewfinder and dedicated menus. Additionally, it offers a "health suite" of services to store data like blood pressure, cholesterol, blood glucose, a drug reminder and ECG monitoring. The user only needs to press two fingers on the phone's edges for 30 seconds for the phone to pick up an ECG reading.

The H'andy sana 211 can enable patients to monitor their health situation on their own, which facilitates their work and leisure activities.

About MedX Health Corp.

MedX is a leading North American developer and manufacturer of low level laser and light medical devices for the drug free and non-invasive treatment of tissue damage and pain in numerous medical settings including dental, rehabilitation and wound care. MedX is the world's only company focusing on developing and delivering a broad cross-section of technologies and products involved in healing using light therapy. MedX is committed to advocating for, the bringing of non-invasive, drug-free healing nature of light to people seeking relief from pain and other physical ailments.

MedX's strategy is to build upon its success in bringing relief of conditions in a non-pharmacologic manner in the rehabilitation market through key partnerships, acquisitions, strong patent protection as well as developing and commercializing advanced products in the dental and wound-care markets that will position the company to increase revenue. In addition, MedX plans to accelerate the development of a new product aimed at the rapidly-growing wound care market: its "Photobandage(TM)", a bandage technology that allows a wound to be bathed in light, designed to enhance the healing process. The Company intends to license this new technology to one or more major wound care companies for further development of marketing and sales.

Brand products are US FDA approved, Health Canada cleared, and CE Marked and are produced in an ISO 9001 and 13485 certified manufacturing and testing facility. For a complete profile of MedX Health Corp. and its products visit www.medXhealth.com

This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company's limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company's projections or forward-looking statements. All forward-looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release.

For further information: Investors: Steve Guillen, President and Chief Executive Officer, MedX Health Corp., Phone: [phone], [email protected]